Global competition for China’s biotechnology innovations is entering a more aggressive phase as venture capital firms increasingly shift their focus toward early stage scientific research rather than waiting for assets to reach commercialization. Investors, particularly from the United States, are embedding themselves directly
Hong Kong listed biotechnology company Insilico Medicine has expanded its global footprint through a new partnership in the United Arab Emirates aimed at accelerating artificial intelligence driven drug discovery. The agreement was signed with the UAE’s national drug regulator during a major healthcare
From trial and error to data driven discovery Drug discovery has traditionally been a slow and uncertain process shaped by trial and error. In China, artificial intelligence is changing this dynamic by introducing data driven methods that compress research timelines and improve decision
China’s biotechnology sector is entering a new phase of scientific acceleration as research laboratories expand their use of automated platforms for drug discovery. These systems combine robotics, artificial intelligence, high-throughput screening, and advanced data analysis tools to reduce the time required to identify
